Cover Image
市場調查報告書

中樞神經系統的合作條件與契約

Global Central Nervous System Partnering 2010-2016: Deal trends, players and financials

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 250308
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
中樞神經系統的合作條件與契約 Global Central Nervous System Partnering 2010-2016: Deal trends, players and financials
出版日期: 2016年09月01日 內容資訊: 英文
簡介

本報告提供中樞神經系統(CNS)的合作相關契約調查分析,全球依各主要醫療企業所簽訂的各種契約趨勢,主要交易,大規模相關交易檢驗,也包含不同市場區隔的契約名錄,為您概述為以下內容。

摘要整理

第1章 簡介

第2章 中樞神經系統的契約趨勢

  • 簡介
  • 常年的中樞神經系統的合作
  • 大型製藥公司的中樞神經系統契約活動
  • 沒進行中樞神經系統的活動的大型製藥公司
  • 中樞神經系統的合作:各交易類型
  • 中樞神經系統的合作:各產品部門
  • 中樞神經系統的合作:各開發階段
  • 中樞神經系統的合作:各技術類型
  • 中樞神經系統的合作:中樞神經系統的各適應症
  • 中樞神經系統的平均交易條件

第3章 主要中樞神經系統的交易

  • 簡介
  • 中樞神經系統的主要交易:各金額
  • 與大型製藥公司有關的中樞神經系統的主要交易

第4章 大型製藥公司的中樞神經系統的交易

  • 簡介
  • 大型製藥公司的合作交易的利用方法
  • 大型製藥公司的中樞神經系統的合作企業簡介

第5章 中樞神經系統的合作契約名錄

  • 簡介
  • 各交易類型
  • 各開發階段
  • 各技術類型

第6章 中樞神經系統的契約:各適應症

  • 簡介
  • 交易:治療各適應症

第7章 合作資訊提供來源

  • 線上合作
  • 合作活動
  • 契約相關參考文獻

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP2203

The ‘Global Central Nervous System Partnering 2010 to 2016: Deal trends, players and financials report’ provides comprehensive understanding and unprecedented access to the central nervous system (cns) partnering deals and agreements entered into by the worlds leading healthcare companies

‘Global Central Nervous System Partnering 2010 to 2016’ provides the full collection of Central Nervous System disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

  • Trends in Central Nervous System partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Central Nervous System partnering agreement structure
  • Central Nervous System partnering contract documents
  • Top Central Nervous System deals by value
  • Most active Central Nervous System dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Central Nervous System disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Central Nervous System deals.

The report presents financial deal terms values for Central Nervous System deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Central Nervous System dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Central Nervous System dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Central Nervous System deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Central Nervous System dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Central Nervous System deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Central Nervous System partnering deals by specific Central Nervous System target announced since 2010. The chapter is organized by specific Central Nervous System therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Central Nervous System partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Central Nervous System partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Central Nervous System technologies and products.

Report scope

‘Global Central Nervous System Partnering 2010 to 2016’ is intended to provide the reader with an in-depth understanding and access to Central Nervous System trends and structure of deals entered into by leading companies worldwide.

‘Global Central Nervous System Partnering 2010 to 2016’ includes:

  • Trends in Central Nervous System dealmaking in the biopharma industry since 2010
  • Analysis of Central Nervous System deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Central Nervous System deal contract documents
  • Comprehensive access to over 3500 Central Nervous System deal records
  • The leading Central Nervous System deals by value since 2010
  • Most active Central Nervous System dealmakers since 2010
  • The report includes deals for the following indications: Cerebral palsy, Creutzfeldt Jakob disease, Dizziness, Epilepsy, Faints, Falls, Guillain Barre syndrome, Headache, Meningitis (Bacterial, Meningococcal, Pneumococcal), Mycobacterium tuberculosis (TB), Haemophilus influenzae Type B (Hib), Migraine, Motor Neurone Disease (Amyotrophic Lateral Sclerosis/Lou Gehrig's Disease, Multiple sclerosis, Nausea, Neuropathy, Pain, Neuralgia, Fibromyalgia, Paralysis, Parkinson's disease, Restless leg syndrome, Spinal cord, Stroke, Stuttering, Traumatic Brain Injury, Vertigo, Weakness, plus other CNS indications.

In ‘Global Central Nervous System Partnering 2010 to 2016’, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Central Nervous System Partnering 2010-2016’ report provides comprehensive access to available deals and contract documents for over 1,500 central nervous system deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

‘Global Central Nervous System Partnering 2010 to 2016’ provides the reader with the following key benefits:

  • In-depth understanding of Central Nervous System deal trends since 2010
  • Access Central Nervous System deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Central Nervous System partner companies
  • Comprehensive access to over 750 links to actual Central Nervous System deals entered into by the world's biopharma companies
  • Indepth review of Central Nervous System deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Central Nervous System opportunities
  • Uncover companies actively partnering Central Nervous System opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Central Nervous System dealmaking

  • 2.1. Introduction
  • 2.2. Central Nervous System partnering over the years
  • 2.3. Central Nervous System partnering by deal type
  • 2.4. Central Nervous System partnering by industry sector
  • 2.5. Central Nervous System partnering by stage of development
  • 2.6. Central Nervous System partnering by technology type
  • 2.7. Central Nervous System partnering by therapeutic indication

Chapter 3 -Financial deal terms for Central Nervous System partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Central Nervous System partnering
  • 3.3. Central Nervous System partnering headline values
  • 3.4. Central Nervous System deal upfront payments
  • 3.5. Central Nervous System deal milestone payments
  • 3.6. Central Nervous System royalty rates

Chapter 4 - Leading Central Nervous System deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Central Nervous System partnering
  • 4.3. List of most active dealmakers in Central Nervous System
  • 4.4. Top Central Nervous System deals by value

Chapter 5 - Central Nervous System contract document directory

  • 5.1. Introduction
  • 5.2. Central Nervous System partnering deals where contract document available

Chapter 6 - Central Nervous System dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Central Nervous System therapeutic target

Appendices

  • Appendix 1 - Directory of Central Nervous System deals by company A-Z 2010 to 2016
  • Appendix 2 - Directory of Central Nervous System deals by deal type 2010 to 2016
  • Appendix 3 - Directory of Central Nervous System deals by stage of development 2010 to 2016
  • Appendix 4 - Directory of Central Nervous System deals by technology type 2010 to 2016
  • Further reading on dealmaking
  • Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Central Nervous System partnering since 2010
  • Figure 2: Central Nervous System partnering by deal type since 2010
  • Figure 3: Central Nervous System partnering by industry sector since 2010
  • Figure 4: Central Nervous System partnering by stage of development since 2010
  • Figure 5: Central Nervous System partnering by technology type since 2010
  • Figure 6: Central Nervous System partnering by indication since 2010
  • Figure 7: Central Nervous System deals with a headline value
  • Figure 8: Central Nervous System deals with upfront payment values
  • Figure 9: Central Nervous System deals with milestone payment
  • Figure 10: Central Nervous System deals with royalty rates
  • Figure 11: Active Central Nervous System dealmaking activity- 2010 to 2016
  • Figure 12: Top Central Nervous System deals by value since 2010
Back to Top